Efgartigimod for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will evaluate the safety, dosing, and effects of this treatment on their daily lives.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Vyvgart
Vyvgart is a medicine used to treat generalized myasthenia gravis, a condition that causes muscle weakness.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Efgartigimod Alfa
Efgartigimod alfa is a substance that lowers harmful antibodies to treat autoimmune conditions such as generalized myasthenia gravis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Universitair Ziekenhuis Antwerpen
Neurology
Wilrijk, Belgium
Centre Hospitalier Regional De Marseille
Centre Hospitalier Universitaire (CHU) Hôpital de La Timone Service de neuro-métabolisme pédiatrique
Marseille, France
Hopital Necker Enfants Malades
Service de Neuropédiatrie
Montrouge, France

Sponsor: Argenx
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.